5-pyrimidinehexanamine | 88940-43-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-pyrimidinehexanamine
• 英文别名: 6-(Pyrimidin-5-YL)hexan-1-amine；6-pyrimidin-5-ylhexan-1-amine
• CAS: 88940-43-6
• 化学式: C₁₀H₁₇N₃
• 分子量: 179.265
• InChiKey: JHBAJAHVXITCEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(1-butyl-4-methoxy-2-naphthalenyl)-2-propenoic acid 4-nitrophenyl ester 、 5-pyrimidinehexanamine 在 乙酸乙酯 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 为溶剂， 反应 17.5h， 以to provide 0.86 g of (E)-3-(1-butyl-4-methoxy-2-naphthalenyl)-N-[6-(5-pyrimidinyl)hexyl]-2-propenamide, mp 128°-129° C的产率得到(E)-3-(1-butyl-4-methoxy-2-naphthalenyl)-N-[6-(5-pyrimidinyl)hexyl]-2-propenamide
  参考文献：
  名称：

  Pyridine compounds which are useful in treating a disease state

  摘要：

  本发明涉及公式##STR1##的化合物，其中Y和Y'为氢或一起取O或S，*A为对苯二甲基或*----（CH.sub.2).sub.n --(X).sub.s --(CH.sub.2).sub.r ----，X为O、S或--CH.dbd.CH--，n或r独立地为0至3的整数，m为0至1的整数，s为0至1的整数，但当s为1时，n+m必须至少为2，t为0至10的整数，R.sub.1和R.sub.2独立地为较低的烷基、较低的烯基或芳基，或R.sub.1或R.sub.2之一为氢，另一个为##STR2##其中W为##STR3## --CH.sub.2 --CH.sub.2 --，--CH.sub.2 --，O，S或##STR4##，X.sub.1为较低的烷基、未取代的苯基或被较低的烷氧基、较低的烷基或卤素单、二或三取代的苯基，X.sub.2、X.sub.3和X.sub.4独立地为氢、较低的烷基、较低的烷氧基或卤素，R.sub.3为氢、较低的烷基或芳基，R.sub.4为氢、较低的烷基、芳基、芳基-较低的烷基或酰基，R.sub.5为氢或较低的烷基，R.sub.6为氢、较低的烷基、环烷基、Het-较低的烷基或芳基，Het是一种含有一个或两个氮原子的单环6成员杂环芳基，该基团可以被较低的烷基、卤素或芳基取代，星号表示附着点，当R.sub.5和R.sub.6不同时，它们的对映异构体和外消旋混合物，当R.sub.1和R.sub.2不同时，它们的几何异构体，以及其药学上可接受的酸添加盐。

  公开号：

  US04927838A1
• 作为产物：
  描述：

  5-己炔-1-醇 在 palladium on activated charcoal bis-triphenylphosphine-palladium(II) chloride 、 氯化亚砜 、 氢气 、 一水合肼 、 三乙胺 、 potassium iodide 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 5-pyrimidinehexanamine
  参考文献：
  名称：

  Pyrido[2,1-b]quinazolinecarboxamide derivatives as platelet activating factor antagonists

  摘要：

  A series of N-[(heteroaryl)alkyl]pyrido[2,1-b]quinazolines were evaluated for their ability to inhibit the binding of radiolabeled platelet activating factor (PAF) to its receptor on dog platelets. The most potent compounds in this series were found to be pyrido[2,1-b]quinazoline-8-carboxamides possessing a four- or six-carbon chain between the carboxamide nitrogen atom and a 3-pyridinyl or 5-pyrimidinyl moiety. Since earlier metabolism studies with pyridoquinazolinecarboxamides suggest that the carboxamide moiety is labile to hydrolysis in vivo, attempts were made to find isosteric replacements for this group. The substitutions examined led to a loss of activity; however, insertion of a methyl group on the carbon atom alpha to the carboxamide nitrogen led to an enantioselective enhancement of potency. (R)-2-(1-Methylethyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-11-oxo-11H- pyrido[2,1-b]quinazoline-8-carboxamide (34) was more potent than the corresponding S enantiomer in the PAF binding assay and was also shown to be more resistant to degradation by amidases present in whole liver homogenates obtained from guinea pig, dog, and squirrel monkey. The corresponding rac-2-(1-methylethyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-11-oxo-11H- pyrido[2,1-b]quinazoline-8-carboxamide (33) was found to inhibit transient PAF-induced thrombocytopenia and decreases in blood pressure in guinea pigs after intravenous or oral administration and to have a duration of action of greater than 5 h after an oral dose of 200 mg/kg. Compound 33 thus represents the prototype of a new class of orally active PAF antagonists.

  DOI：

  10.1021/jm00397a034

文献信息

• Novel pyridyl cyanoguanidine compounds
  申请人：——

  公开号：US20040220408A1

  公开（公告）日：2004-11-04

  Compounds according to formula (I) 1 wherein R1 represents hydrogen, halogen or one or more straight or branched, saturated or unsaturated C 1-6 hydrocarbon radical, optionally substituted with halogen, hydroxy, cyano, nitro, carboxy, alkoxy, alkoxycarbonyl, alkylcarbonyl, formyl, amico, aminoalkyl, aminocarbonyl, alkylcarbonylamino, sulfo, aminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, dihydroxyphosphinoyloxy or phosphono; X represents a straight or branched, saturated or unsaturated C 1-12 hydrocarbon diradical, optionaly substituted with halogen, hydroxy, cyano, nitro, carboxy, alkoxy, alkoxycarbonyl, alkylcarbonyl, formyl, amino, aminoalkyl, aminocarbonyl, alkylcarbonylamino, sulfo, aminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, dihydroxyphosphinoyloxy or phosphono; Y represents a bond, O, C(O), S, S(O), S(O) 2 , C(O)O, NH, C(O)NH, OC(O) or NHC(O); Z represents an aromatic or non-aromatic heterocyclic radical with 5-12 ring atoms, optionally substituted with halogen, hydroxy, cyano, nitro, alkoxy, alkoxycarbonyl, alkylcarbonyl, formyl, aminoalkyl or straight or branched, saturated or unsaturated C 1-4 hydrocarbon radical, optionally substituted with halogen, hydroxy, cyano, nitro, alkoxy, alkoxycarbonyl, alkylcarbonyl, formyl or aminoalkyl; provided that R1 is not attached to the nitrogen-atom in the pyridyl ring, and pharmaceutically acceptable salts, solvates, hydrates, N-oxides and prodrugs thereof are disclosed. The compounds are useful in therapy.

  根据式（I）1，其中R1代表氢，卤素或一个或多个直链或支链、饱和或不饱和的C1-6烃基，可选地用卤素、羟基、氰基、硝基、羧基、烷氧基、烷氧羰基、烷基羰基、甲酰基、酰胺基、氨基烷基、氨基羰基、烷基酰胺基、磺酸基、氨基磺酰基、烷基磺酰胺基、羟基磺酰氧基、二羟基膦酰氧基或磷酸基取代；X代表直链或支链、饱和或不饱和的C1-12双基，可选地用卤素、羟基、氰基、硝基、羧基、烷氧基、烷氧羰基、烷基羰基、甲酰基、氨基、氨基烷基、氨基羰基、烷基酰胺基、磺酸基、氨基磺酰基、烷基磺酰胺基、羟基磺酰氧基、二羟基膦酰氧基或磷酸基取代；Y代表键、O、C（O）、S、S（O）、S（O）2、C（O）O、NH、C（O）NH、OC（O）或NHC（O）；Z代表具有5-12个环原子的芳香或非芳香杂环基，可选地用卤素、羟基、氰基、硝基、烷氧基、烷氧羰基、烷基羰基、甲酰基、氨基烷基或直链或支链、饱和或不饱和的C1-4烃基，可选地用卤素、羟基、氰基、硝基、烷氧基、烷氧羰基、烷基羰基、甲酰基或氨基烷基取代；但要求R1不连接到吡啶环中的氮原子，并且公开了其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和前药。这些化合物在治疗中有用。
• Pyrido[2,1-b]quinazoline derivatives useful as agents for treatment of
  申请人：Hoffmann-La Roche Inc.

  公开号：US04551460A1

  公开（公告）日：1985-11-05

  Pyrido[2,1-b]quinazoline derivatives of the formulas ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as hereinafter set forth, are described. The compounds of formulas I and II are useful as agents for the treatment of allergic conditions as well as for the treatment of vascular disorders involving thrombosis.

  本文描述了式子##STR1##中R.sub.1，R.sub.2和R.sub.3的衍生物。 公式I和II的化合物可用作过敏症的治疗剂以及涉及血栓形成的血管障碍的治疗剂。
• Substituted alkene carboxylic acid amides and derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0298466A2

  公开（公告）日：1989-01-11

  There are described compounds of the general formula wherein Y and Y′ are hydrogen or taken together are O or S, *A is paraphenylene or *-(CH₂)n-(X)s-(CH₂)r-, X is O, S or -CH=CH-, n and r, independently are integers from 0 to 3, m is the integer 0 or 1, s is the integer 0 or 1, provided that when s is 1, n+m is at least 2, t is an integer from 0 to 10, R₁ and R₂, independently, are lower alkyl, lower alkenyl or aryl, or one of R₁ and R₂ is hydrogen and the other is W is -CX₃=CX₄-, -CH₂-CH₂-, -CH₂-, O, S or -NX₅-, X₁ is lower alkyl, phenyl or phenyl with up to 3 substituents selected from lower alkoxy, lower alkyl and halogen, X₂, X₃ and X₄, independently, are hydrogen, lower alkyl, lower alkoxy or halogen, X₅ is lower alkyl, R₃ is hydrogen, lower alkyl or aryl, R₄ is hydrogen, lower alkyl, aryl, aryl-lower alkyl or acyl, R₅ is hydrogen or lower alkyl, R₆ is hydrogen,     lower alkyl, lower cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 6-membered heteroaromatic radical containing one or two nitrogen atoms, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, when R₅ and R₆ are different, enantiomers and racemic mixtures thereof, when R₁ and R₂ are different, geometric isomers thereof, and pharmaceutically acceptable acid addition salts thereof. These compounds exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shocks or transplant rejections.

  所述化合物通式如下 其中 Y 和 Y′为氢或合起来为 O 或 S，*A 为对苯二甲酸或 *-(CH₂)n-(X)s-(CH₂)r-，X 为 O、S 或-CH=CH-，n 和 r 独立地为 0 至 3 的整数，m 为 0 或 1 的整数、s 是 0 或 1 的整数，条件是当 s 为 1 时，n+m 至少为 2，t 是 0 至 10 的整数，R₁ 和 R₂ 独立地是低级烷基、低级烯基或芳基，或者 R₁ 和 R₂ 中的一个是氢，另一个是 W 是-CX₃=CX₄-、-CH₂-CH₂-、-CH₂-、O、S 或-NX₅-，X₁ 是低级烷基、苯基或带有最多 3 个选自低级烷氧基、低级烷基和卤素的取代基的苯基，X₂、X₃ 和 X₄ 独立地、是氢、低级烷基、低级烷氧基或卤素，X₅ 是低级烷基，R₃ 是氢、低级烷基或芳基，R₄ 是氢、低级烷基、芳基、芳基-低级烷基或酰基，R₅ 是氢或低级烷基，R₆ 是氢、 R₅是氢或低级烷基，R₆是氢、低级烷基、低级环烷基、Het-低级烷基或芳基，Het 是含有一个或两个氮原子的单环六元杂芳基，该基可被低级烷基、卤素或芳基取代，星号表示连接点、 当 R₅ 和 R₆ 不同时，其对映体和外消旋混合物；当 R₁ 和 R₂ 不同时，其几何异构体；以及其药学上可接受的酸加成盐。 这些化合物具有血小板活化因子（PAF）拮抗剂的活性，因此可用于以血小板活化因子过量为特征的疾病状态，或用于预防和治疗心血管疾病、肺部疾病、免疫性疾病、炎症性疾病、皮肤病、休克或移植排斥反应。
• TILLEY, JEFFERSON W.;BURGHARD, BARBARA;BURGHARDT, CHARLES;MOWLES, THOMAS +, J. MED. CHEM., 31,(1988) N 2, 466-472
  作者：TILLEY, JEFFERSON W.、BURGHARD, BARBARA、BURGHARDT, CHARLES、MOWLES, THOMAS +

  DOI：——

  日期：——
• Pyrido(2,1-b)chinazolinderivate
  申请人：F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft

  公开号：EP0094080B1

  公开（公告）日：1987-09-09